Differential ligand activation of estrogen receptors ERα and ERrβ at AP1 sites

Science

Volumn 277, Issue 5331, 1997, Pages 1508-1510

  Paech, Kolja ^a   Webb, Paul ^a   Kuiper, George G J M ^b   Nilsson, Stefan ^c   Gustafsson, Jan Åke ^b   Kushner, Peter J ^a   Scanlan, Thomas S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Karo Bio   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RALOXIFENE; RECEPTOR SUBTYPE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG STRUCTURE; GENE EXPRESSION REGULATION; HELA CELL; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE; DIETHYLSTILBESTROL; ENHANCER ELEMENTS (GENETICS); ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HELA CELLS; HUMANS; LIGANDS; PIPERIDINES; POLYUNSATURATED ALKAMIDES; RALOXIFENE; RATS; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTOR AP-1; TRANSFECTION; TUMOR CELLS, CULTURED; UTERUS;

EID: 0030801841     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.277.5331.1508     Document Type: Article

References (27)

1. D. J. Grainger and J. C. Metcalfe, Nature Med. 2, 381 (1996).
2. R. P. Kedar et al., Lancet 343, 1318 (1994).
3. C. D. Jones et al., J. Med. Chem. 27, 1057 (1984).
4. L. J. Black et al., J. Clin. Invest. 93, 63 (1994).
5. M. Sato, M. K. Rippy, H. U. Bryant, FASEB J. 10, 905 (1996).
6. N. N. Yang et al., Endocrinology 137, 2075 (1996).
7. N. N. Yang, M. Venugopalan, S. Hardikar, A. Glasebrook, Science 273, 1222 (1996).
8. Y. Umayahara et al., J. Biol. Chem. 269, 16433 (1994); M.-P. Gaub, M. Bellard, I. Sheuer, P. Chambon, P. Sassone-Corsi, Cell 63, 1267 (1990); A. Weisz and R. Resales, Nucleic Acids Res. 18, 5097 (1990).
9. Y. Umayahara et al., J. Biol. Chem. 269, 16433 (1994); M.-P. Gaub, M. Bellard, I. Sheuer, P. Chambon, P. Sassone-Corsi, Cell 63, 1267 (1990); A. Weisz and R. Resales, Nucleic Acids Res. 18, 5097 (1990).
10. Y. Umayahara et al., J. Biol. Chem. 269, 16433 (1994); M.-P. Gaub, M. Bellard, I. Sheuer, P. Chambon, P. Sassone-Corsi, Cell 63, 1267 (1990); A. Weisz and R. Resales, Nucleic Acids Res. 18, 5097 (1990).
11. P. Webb, G. N. Lopez, R. M. Uht, P. J. Kushner, Mol. Endocrinol. 9, 443 (1995).
12. G. G. J. M. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, J.-Å. Gustafsson, Proc. Natl. Acad. Sci. U.S.A. 93, 5925 (1996).
13. S. Mosselman, J. Polman, R. Dijkema, FEBS Lett. 392, 49 (1996).
14. G. B. Tremblay et al., Mol. Endocrinol. 11, 353 (1997).
15. The ERE- and AP1-driven luciferase reporter plasmids [(EREII-Luc GL450) and Δcoll73, respectively] and the ERα expression plasmid (pSG5-HEO) were used as previously described (9). The rat ERβ expression vector has been previously described (10). The full-length human ERβ cDNA, which was isolated from an ovarian cDNA library and found to be identical to the previously reported partial cDNA clone (11), was cloned into the pCMV5 eukaryotic expression vector (E. Enmark et al., unpublished data), and the resulting ERβ expression vector was used for these experiments. Western blotting of rat mammary gland and prostate nuclear extracts probed with polyclonal antibodies raised against ERβ ligand-binding domain (LBD) and preadsorbed on a column of ERα LBD-coupled Sepharose showed that in both breast and prostate nuclear extracts the major band recognized by the antibody has the same mobility as full-length bacculovirus-expressed ERβ. This indicates that our ERβ expression vector encodes the major isoform of ERβ in these tissues (T. Rylander, M. P. Huikko, J.-Å. Gustafsson, unpublished data).
16. The data presented in this paper were obtained with the HEO ERα variant. HEO shows reduced transactivation response from the unliganded receptor compared with the wild-type ERα, resulting in clearer ligand-induced transactivation data. Each experiment with ERα was also checked with the wild-type ERα (HEGO), and the general ligand induction trends were found to be the same as those obtained with HEO. The only difference was that the ligand-induced transactivation responses were lower with HEGO than with the control (no ligand added).
17. Transactivation experiments were performed with both rat and human ERβ, and identical trends in ligand behavior were seen with both ERβs in HeLa cells.
18. 13C NMR, ultraviolet spectroscopy, thin-layer chromatography, and high-resolution mass spectrometry.
19. 4, 4 mM EGTA, and 15 mM potassium phosphate at pH 7.8, with the addition of DTT to a final concentration of 1 mM, adenosine triphosphate to a final concentration of 2 mM, and luciferin (Analytical Luminescence Laboratories) to a final concentration of 200 μM shortly before commencement of the assay. Luminescence measurements were performed on a Monolight 1500 (Analytical Luminescence Laboratories). The relative light units reported have been adjusted to a scale of 100 for uniformity.
20. K. Paech et al., unpublished data.
21. The human ERβ was used for transactivation experiments in Ishikawa, MDA453, and MCF7 cells.
22. G. G. J. M. Kuiper et al., Endocrinology 138, 863 (1997); K. Grandien et al., unpublished data.
23. D. J. Mangelsdorf et al., Cell 83, 835 (1996).
24. J. A. Katzenellenbogen and B. S. Katzenellenbogen, Chem. Biol. 3, 529 (1996).
25. D. J. Mangelsdorf and R. M. Evans, Cell 83, 841 (1996).
26. 2 is a transcription inhibitor.
27. Supported by grants from NIH (GM 50672 to T.S.S.), the Swedish Cancer Society (J.-Å.G.), and the U.S. Army and University of California Breast Cancer Research Programs (P.J.K.). We thank K. Yamamoto and R. Weatherman for helpful discussions.